We are live on ! Find out more
SC

Stralem & Co Portfolio holdings

AUM $157M
1-Year Est. Return 4.29%
This Fund
S&P 500
This Quarter Est. Return
+3.25%
1 Year Est. Return
+4.29%
3 Year Est. Return
+25.48%
5 Year Est. Return
+55.56%
10 Year Est. Return
–
AUM
$695M
AUM Growth
-$161M
Cap. Flow
-$181M
Cap. Flow %
-26.08%
Top 10 Hldgs %
32.98%
Holding
49
New
1
Increased
3
Reduced
38
Closed
2

Top Buys

Rank Stock Value
1
APTV icon
Aptiv
APTV
+$20.2M
2
COST icon
Costco
COST
+$110K
3
LLY icon
Eli Lilly
LLY
+$49.2K
4
BMY icon
Bristol-Myers Squibb
BMY
+$29.2K

Top Sells

Rank Stock Value
1
SLB icon
SLB Ltd
SLB
+$19.5M
2
META icon
Meta Platforms (Facebook)
META
+$7.63M
3
V icon
Visa
V
+$7.09M
4
ADBE icon
Adobe
ADBE
+$7M
5
UNH icon
UnitedHealth
UNH
+$6.84M

Sector Composition

Rank Sector Weight
1 Healthcare 24.17%
2 Technology 13.06%
3 Communication Services 12.01%
4 Utilities 8.97%
5 Financials 8.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KHC icon
26
Kraft Heinz
KHC
$29.1B
$18.4M 2.65%
237,190
-52,440
-18% -$4.39M
ABT icon
27
Abbott
ABT
$192B
$16M 2.3%
298,975
-78,780
-21% -$3.95M
AMGN icon
28
Amgen
AMGN
$225B
$15.3M 2.2%
81,855
-20,760
-20% -$3.68M
CVX icon
29
Chevron
CVX
$386B
$15M 2.16%
127,645
-33,260
-21% -$3.63M
EOG icon
30
EOG Resources
EOG
$75.1B
$14.9M 2.15%
154,160
-37,970
-20% -$3.43M
CELG
31
DELISTED
Celgene Corp
CELG
$14.8M 2.13%
101,583
-33,822
-25% -$4.61M
TMO icon
32
Thermo Fisher Scientific
TMO
$223B
$14.7M 2.12%
77,735
-26,960
-26% -$4.88M
CB icon
33
Chubb
CB
$132B
$14.6M 2.1%
102,345
-27,850
-21% -$4.03M
JNJ icon
34
Johnson & Johnson
JNJ
$629B
$13.9M 2.01%
107,260
-30,310
-22% -$4.02M
XOM icon
35
ExxonMobil
XOM
$657B
$13.6M 1.96%
166,120
-40,400
-20% -$3.21M
BMY icon
36
Bristol-Myers Squibb
BMY
$130B
$3.24M 0.47%
50,900
+500
+1% +$29.2K
KO icon
37
Coca-Cola
KO
$373B
$1.51M 0.22%
33,600
-600
-2% -$27.3K
ADP icon
38
Automatic Data Processing
ADP
$107B
$1.15M 0.17%
10,500
– –
FE icon
39
FirstEnergy
FE
$27.2B
$1.14M 0.16%
37,100
– –
LLY icon
40
Eli Lilly
LLY
$1.09T
$1.13M 0.16%
13,200
+600
+5% +$49.2K
A icon
41
Agilent Technologies
A
$41.9B
$1.08M 0.16%
16,800
-1,100
-6% -$68.5K
IFF icon
42
International Flavors & Fragrances
IFF
$21.4B
$1.07M 0.15%
7,500
– –
NVDA icon
43
NVIDIA
NVDA
$5.43T
$1.05M 0.15%
236,000
-84,000
-26% -$349K
COST icon
44
Costco
COST
$421B
$1.03M 0.15%
6,300
+700
+13% +$110K
AAPL icon
45
Apple
AAPL
$4.41T
$986K 0.14%
25,600
– –
GILD icon
46
Gilead Sciences
GILD
$168B
$980K 0.14%
12,100
-700
-5% -$53.5K
ZBH icon
47
Zimmer Biomet
ZBH
$18.7B
$785K 0.11%
6,901
– –
CL icon
48
Colgate-Palmolive
CL
$73.6B
– –
-12,700
Closed -$941K
SLB icon
49
SLB Ltd
SLB
$78.1B
– –
-295,760
Closed -$19.5M
1
2

Similar funds

LI
Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return
BC
Blackstart Capital New York $151M AUM 14.01% 1-Year Est. Return
JT
Jump Trading Chicago, Illinois $150M AUM 17.61% 1-Year Est. Return
SCM
Stellar Capital Management Phoenix, Arizona $147M AUM 5.91% 1-Year Est. Return
HF
Hellman & Friedman San Francisco, California $169M AUM
SMFS
Squar Milner Financial Services Irvine, California $176M AUM 10.56% 1-Year Est. Return
CCM
Cloverdale Capital Management Dallas, Texas $135M AUM 13.89% 1-Year Est. Return
CCM
Castine Capital Management Boston, Massachusetts $129M AUM 23.45% 1-Year Est. Return

Stralem & Co's Q3 2017 Portfolio in Review

As of Q3 2017, Stralem & Co held 49 positions worth $695M, down 19% from $855M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Stralem & Co withdrew a net $181M in Q3 2017, closing 2 positions and reducing 38 holdings. Its most notable exit was SLB Ltd, an estimated $19.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 24% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Stralem & Co opened a new position in Aptiv worth $21.1M.

  • Stralem & Co's largest Q3 2017 buy was Aptiv: 214,550 shares worth $21.1M.
  • Stralem & Co added most to Costco in Q3 2017, an estimated $110K increase.
  • Stralem & Co's biggest Q3 2017 reduction was Meta Platforms (Facebook), cutting an estimated $7.63M.
  • Stralem & Co fully exited SLB Ltd in Q3 2017, selling an estimated $19.5M.
  • Stralem & Co's ten largest holdings make up 33% of its $695M portfolio in Q3 2017.
  • Stralem & Co opened 1 new position and closed 2 in Q3 2017.
  • Stralem & Co's portfolio value fell 19% quarter-over-quarter to $695M.

Based on Stralem & Co's 13F filing for Q3 2017, filed 16 Oct 2017.